Inimmune Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 36

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2M

  • Investors
  • 4

Inimmune General Information

Description

Operator of a biotechnology company intended to offer treatment for allergy, autoimmunity, and cancer in patients. The company focuses on the prevention of upper respiratory tract infections by targeting innate immune receptors, enabling medical researchers to easily find a cure for patients with respiratory illnesses.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1121 East Broadway Street
  • Suite 106
  • Missoula, MT 59802
  • United States
+1 (406)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1121 East Broadway Street
  • Suite 106
  • Missoula, MT 59802
  • United States
+1 (406)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 02-Feb-2022 $2M Completed Clinical Trials - Phase 1
6. Later Stage VC (Series A) 02-Feb-2022 Completed Clinical Trials - Phase 1
5. Grant 01-Jan-2021 Completed Clinical Trials - Phase 1
4. Grant 01-Jan-2019 Completed Clinical Trials - Phase 1
3. Grant 09-Feb-2018 Completed Clinical Trials - Phase 1
2. Grant 01-Jan-2018 $769K Completed Clinical Trials - Phase 1
1. Accelerator/Incubator 01-Jan-2016 Completed Clinical Trials - Phase 1
To view Inimmune’s complete valuation and funding history, request access »

Inimmune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2
Series A1
To view Inimmune’s complete cap table history, request access »

Inimmune Patents

Inimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026193322-A1 Semi-synthetic saponin compounds Pending 12-Mar-2025
WO-2025240407-A1 Intranasal administration of toll-like receptor 4 agonists for treating allergic rhinitis and other diseases and conditions Pending 14-May-2024
AU-2025207658-A1 Functionalized imidazopyrimidine compounds and uses thereof Pending 10-Jan-2024
WO-2025151620-A1 Functionalized imidazopyrimidine compounds and uses thereof Inactive 10-Jan-2024
EP-4561992-A2 Stimulator of interferon genes agonists Pending 25-Jul-2022 A61K31/5415
To view Inimmune’s complete patent history, request access »

Inimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inimmune Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
McWin Partners Family Office Minority
Two Bear Capital Venture Capital Minority
National Institute Of Allergy and Infectious Diseases Government
U.S. Department of Health and Human Services Government
To view Inimmune’s complete investors history, request access »

Inimmune FAQs

  • When was Inimmune founded?

    Inimmune was founded in 2016.

  • Where is Inimmune headquartered?

    Inimmune is headquartered in Missoula, MT.

  • What is the size of Inimmune?

    Inimmune has 36 total employees.

  • What industry is Inimmune in?

    Inimmune’s primary industry is Drug Discovery.

  • Is Inimmune a private or public company?

    Inimmune is a Private company.

  • What is Inimmune’s current revenue?

    The current revenue for Inimmune is .

  • How much funding has Inimmune raised over time?

    Inimmune has raised $22M.

  • Who are Inimmune’s investors?

    McWin Partners, Two Bear Capital, National Institute Of Allergy and Infectious Diseases, and U.S. Department of Health and Human Services have invested in Inimmune.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process